专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR1020060109595A 개선된 측면 이동 면역분석법과 이를 위한 디바이스 失效
标题翻译：改进的横向流动免疫和其设备
公开(公告)号：KR1020060109595A
公开(公告)日：2006-10-23
申请号：KR1020050031755
申请日：2005-04-18
申请人： 주식회사 엘지생명과학
发明人： 유승범 , 손미진 , 오재훈 , 김은경
IPC分类号： G01N33/53
摘要： An improved lateral flow immunoassay and a device therefor are provided to enhance sensitivity of indirect immunoassay and improve the hook effect caused by high concentration target material to be assayed. The lateral flow immunoassay, which induces antigen-antibody reaction by laterally flowing the solution containing a sample on a solid support fixing the capturing molecule such as antigen or antibody, comprises firstly inducing the reaction between the fixed capture molecule in the solid support and a target material to be assayed in the sample, and secondly inducing the reaction between the capture molecule-target material complex and a marking conjugate, wherein the immunoassay is a noncompetitive immunoassay for detecting the specific antibody by using a second antibody or the antibody-specific protein; the solution flowing is induced by using chromatography, capillary tube phenomenon, electric flowing, pump, centrifugation or magnetic field; the solid support is made of nitrocellulose, polyvinylidene fluoride or nylon; and the marker of the marking conjugate is metal marker, chromogenic enzyme, fluorescence material, luminescence material or dye.
摘要翻译：提供改进的侧流免疫测定及其装置，以提高间接免疫测定的灵敏度，并改善由待测定的高浓度靶物质引起的钩效应。通过横向流动含有样品的固体支持物（例如抗原或抗体）的固体支持物来诱导抗原 - 抗体反应的侧向流动免疫测定包括首先诱导固体支持物中的固定捕获分子与靶在样品中待测定的材料，其次诱导捕获分子 - 靶材料复合物和标记缀合物之间的反应，其中所述免疫测定是通过使用第二抗体或抗体特异性蛋白检测特异性抗体的非竞争性免疫测定; 流动的溶液通过色谱，毛细管现象，电流，泵，离心或磁场诱导; 固体支持物由硝化纤维素，聚偏二氟乙烯或尼龙制成; 标记缀合物的标记是金属标记，显色酶，荧光材料，发光材料或染料。

2. 发明公开

KR1020060000985A 말라리아 플라스모듐 팔시파룸의 면역학적 측정방법 및이에 사용되는 측정 수단 有权
标题翻译：免疫球蛋白及其所用的方法
公开(公告)号：KR1020060000985A
公开(公告)日：2006-01-06
申请号：KR1020040049985
申请日：2004-06-30
申请人： 주식회사 엘지생명과학
发明人： 손미진 , 유승범 , 김연철 , 오재훈 , 김은경 , 추승호
IPC分类号： G01N33/549
CPC分类号： G01N33/56905 , G01N33/543 , G01N2333/445 , Y02A50/58 , G01N33/54386 , G01N2333/44
摘要： Disclosed are an immunoassay of Plasmodium falciparum for determining the presence/absence of a specific and/or antibody thereof via label in conjugates bound to the specific antigen and/or antibody present in a sample, comprising immobilizing the specific antigen and antibody of Plasmodium falciparum on a solid phase, adding a sample obtained from a subject of interest to the solid phase so as to induce specific antibody-antigen reaction, adding a conjugate of the antigen and a label and a conjugate of the antibody and a label, separately prepared, so as to induce binding of at least one of the conjugates; and an assay device comprising the above-mentioned solid phase and conjugates. The present invention can effect specific detection of antigens and/or antibodies in patients with manifested malaria-symptoms as well as malaria carriers and can also be efficiently employed in samples at the early stage of malaria infection that is difficult to detect via conventional arts. Further, due to the capacity to utilize sera and blood plasma rather than whole blood, the present invention is well suited to large-scale examination such as blood screening.

3. 发明公开

KR1020010103188A 3-하이드록시크로멘-4-온 구조를 갖는 ＣＤＫ 저해제 无效
标题翻译：具有3-羟基-4-酮结构的CDK抑制剂
公开(公告)号：KR1020010103188A
公开(公告)日：2001-11-23
申请号：KR1020000023705
申请日：2000-05-03
申请人： 주식회사 엘지생명과학
发明人： 홍창용 , 이진호 , 박태식 , 김종현 , 최세현 , 윤숙경 , 정현호 , 손호선 , 김은경 , 노성구
IPC分类号： C07D311/30
摘要： 본 발명은 사이클린 의존 키나아제(Cyclin Dependent Kinase; 이하, "CDK"라 한다)의 저해제로서 유용한 하기 화학식 1의 신규한 화합물, 그의 약제학적으로 허용되는 염, 수화물, 용매화물 및 이성체에 관한 것이다. 본 발명은 또한, 화학식 1의 화합물을 제조하는 방법 및 약제학적으로 허용되는 담체와 함께 화학식 1의 화합물을 활성성분으로 함유함을 특징으로 하는 항암제 조성물에 관한 것이다.

상기식에서, A, X, Y 및 Z 는 명세서에 정의된 바와 같다.

4. 发明公开

KR1020010086657A 아미노인다졸 유도체 및 이를 함유하는 싸이클린 의존키나아제 저해제 조성물 无效
标题翻译：氨基吖啶衍生物和循环激素依赖性激酶抑制组合物
公开(公告)号：KR1020010086657A
公开(公告)日：2001-09-15
申请号：KR1020000010319
申请日：2000-03-02
申请人： 주식회사 엘지생명과학
发明人： 이진호 , 홍창용 , 김종현 , 박태식 , 최세현 , 윤숙경 , 김동명 , 손호선 , 김은경 , 노성구
IPC分类号： C07D235/10
摘要： PURPOSE: Provided is a novel compound which has an aminoindazole structure and inhibits the activity of cyclin dependent kinase(CDK), thereby exhibiting the inhibition and treatment effects on cell growth related diseases. And a preparation thereof is also provided. CONSTITUTION: The novel aminoindazole derivative is represented by formula (1). In the formula, W is hydrogen, SO2, CH2 or aromatic compound; and X is hydrogen, NH, NO, NR3, O, S, SO, So2, Co, or CH2. A novel compounds is one of followings: 1H-indazole-3-amine, N-isopentyl-1H-indazole-3-amine, N-benzyl-1H-indazole-3-amine, N-(1H-indazole-3-yl)-4-methylbenzenesulfonamide, 4-methyl-N-(5-nitro-1H-indazole-3-yl)benzenesulfonamide, N-(5-amino-1H-indazole-3-yl)-4-methylbenzenesulfonamide, N-{5-£3,5-dihydroxybenzyl)amino|-1H-indazole-3-yl}-4-methylbenzenesulfonamide,N-{5-£(1H-imidazole-2-yl methyl)amino|-1H-indazole-3-yl}-4-methylbenzenesulfonamide,N-{5-£3,4-dihydroxybenzyl)amino-1H-indazole-3-yl}-4-methylbenzenesulfonamide,N-{5-£3,4-dihydroxybutyl)amino|-1H-indazole-3-yl}-4-methylbenzenesulfonamide,N-(5-{£(ethylamino)carbonyl|amino|-1H-indazole-3-yl)-4-methylbenzenesulfonamide,N-(4-bromophenyl)-1H-indazole-3-amine, N-(4-nitrophenyl)-1H-indazole-3-amine, tert-butyl 4-{£4-(1H-indazole-3-yl amino)anilino|carbonyl}-1-piperidinecarboxylate, and N-£5-(diethylamino)-1H-indazole-3-yl|-N-{4-£2-(1-piperidinyl)ethyl|phenyl}amine.
摘要翻译：目的：提供具有氨基吲唑结构并抑制细胞周期蛋白依赖性激酶（CDK）活性的新型化合物，从而对细胞生长相关疾病具有抑制和治疗作用。并提供其制备方法。构成：新型氨基吲唑衍生物由式（1）表示。在该式中，W是氢，SO 2，CH 2或芳族化合物; 并且X是氢，NH，NO，NR 3，O，S，SO，So 2，Co或CH 2。一种新型化合物是以下之一：1H-吲唑-3-胺，N-异戊基-1H-吲唑-3-胺，N-苄基-1H-吲唑-3-胺，N-（1H-吲唑-3-基））-4-甲基苯磺酰胺，4-甲基-N-（5-硝基-1H-吲唑-3-基）苯磺酰胺，N-（5-氨基-1H-吲唑-3-基）-4-甲基苯磺酰胺，N- { 5- {3,5-二羟基苄基}氨基} -1H-吲唑-3-基} -4-甲基苯磺酰胺，N- {5-（1H-咪唑-2-基甲基）氨基} -1H-吲唑-3-基）基} -4-甲基苯磺酰胺，N- {5-£3,4-二羟基苄基）氨基-1H-吲唑-3-基} -4-甲基苯磺酰胺，N- {5-£3,4-二羟基丁基）氨基| -1H - 吲唑-3-基} -4-甲基苯磺酰胺，N-（5- {£（乙基氨基）羰基|氨基| -1H-吲唑-3-基）-4-甲基苯磺酰胺，N-（4-溴苯基）-1H- 吲唑-3-胺，N-（4-硝基苯基）-1H-吲唑-3-胺，4- {4-（1H-吲唑-3-基氨基）苯胺基|羰基} -1-哌啶羧酸叔丁酯，和N- {5-（二乙基氨基）-1H-吲唑-3-基} -N- {4- {2-（1-哌啶基）乙基}苯基}胺。

5. 发明授权

KR101035111B1 말라리아 플라스모듐 팔시파룸의 면역학적 측정방법 및이에 사용되는 측정 수단 有权
标题翻译：对恶性疟原虫进行免疫测定及其用途
公开(公告)号：KR101035111B1
公开(公告)日：2011-05-19
申请号：KR1020040049985
申请日：2004-06-30
申请人： 주식회사 엘지생명과학
发明人： 손미진 , 유승범 , 김연철 , 오재훈 , 김은경 , 추승호
IPC分类号： G01N33/549
CPC分类号： G01N33/56905 , G01N33/543 , G01N2333/445 , Y02A50/58
摘要： 본 발명은 말라리아 플라스모듐 팔시파룸(
Plasmodium falciparum )의 면역학적 측정방법 및 이에 사용되는 측정수단에 관한 것으로, 말라리아 원충 플라스모듐 팔시파룸 (
Plasmodium falciparum )의 특이 항원과 항체를 함께 고정체에 고정시키고, 대상 객체로부터 얻은 검체를 상기 고정체에 가하여 항원과 이에 특이적인 항체반응을 유도한 후, 별도로 준비한 상기 항원과 표지체의 접합체 및 상기 항체와 표지체의 접합체를 첨가하여, 상기 접합체들 중의 적어도 하나의 결합을 유도함으로써, 상기 검체 중의 상기 특이 항원 및/또는 항체에 결합된 접합체 중의 표지체에 의해, 상기 특이 항원 및/또는 항체의 존재 유무를 측정하는 방법, 및 상기 고정체와 접합체들을 포함하는 것으로 구성되어 있는 측정수단을 제공한다.
본 발명에 따르면, 말라리아 현증 환자뿐만 아니라 보균자까지도 특이적으로 검출할 수 있고, 종래의 기술로는 검출하기 힘든 감염 초기의 검체에 대해서도 매우 효율적으로 사용될 수 있다. 또한, 전혈이 아닌 혈청, 혈장 등을 사용할 수 있으므로, 혈액 스크리닝과 같은 대량 검사에도 매우 적합한 형태로 사용될 수 있다.

6. 发明授权

KR100466382B1 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트 有权
标题翻译： 인간면역결핍바이러스-1，-2타입의단백질이융합된재조합콤보단백질，이의생산방법，이를포함하는벡터，형질전환된대장균진단단트
公开(公告)号：KR100466382B1
公开(公告)日：2005-01-14
申请号：KR1020020000896
申请日：2002-01-08
申请人： 주식회사 엘지생명과학
发明人： 손미진 , 김은경 , 유승범 , 김형철 , 이상익 , 오재훈
IPC分类号： C07K19/00
摘要： PURPOSE: A recombinant combo protein fused with HIV type-1, -2 and 0 proteins, a manufacturing method thereof, a vector containing the same and a transformant thereof, a diagnostic kit thereof and a composition for vaccine thereof are provided. The recombinant combo protein has improved HIV antibody sensitivity and specificity. CONSTITUTION: A single stranded polypeptide fusion protein includes entire or a part of HIV type-1 p24 or gp41, HIV type-2 gp36, HIV type-1 group 0 gp41, wherein the HIV type-1 p24 protein contains entire or a part of the amino acid sequence of SEQ ID NO: 7; the HIV type-1 gp41 protein contains entire or a part of the amino acid sequence of SEQ ID NO: 8; the HIV type-2 gp36 protein contains entire or a part of the amino acid sequence of SEQ ID NO: 9; the HIV type-1 group 0 gp41 protein contains entire or a part of the amino acid sequence of SEQ ID NO: 10; and six-repeated histidine residue is positioned at the C-terminal of the fusion protein. An expression vector pLCSK-1 contains the fusion protein gene. A transformed E. coli(KCTC 10100BP) is produced by transformation with the expression vector pLCSK-1.
摘要翻译：目的：提供与HIV-1，-2和0型蛋白融合的重组组合蛋白，其制备方法，含有该蛋白的载体及其转化体，其诊断试剂盒及其疫苗组合物。重组组合蛋白具有提高的HIV抗体敏感性和特异性。构成：单链多肽融合蛋白包括HIV1型p24或gp41，HIV2型gp36，HIV1型0组gp41的全部或部分，其中HIV1型p24蛋白含有全部或部分的 SEQ ID NO：7的氨基酸序列; HIV1型gp41蛋白含有SEQ ID NO：8的全部或部分氨基酸序列; HIV2型gp36蛋白含有SEQ ID NO：9的全部或部分氨基酸序列; HIV1型组0gp41蛋白含有SEQ ID NO：10的全部或部分氨基酸序列; 并且六重复组氨酸残基位于融合蛋白的C-末端。表达载体pLCSK-1含有融合蛋白基因。转化的大肠杆菌（KCTC 10100BP）通过用表达载体pLCSK-1转化而产生。

7. 发明公开

KR1020030080810A 아미노피리도아릴 그룹을 가진 선택적 트롬빈 억제제 无效
标题翻译：具有氨基吡啶类的选择性硫蛋白抑制剂
公开(公告)号：KR1020030080810A
公开(公告)日：2003-10-17
申请号：KR1020020019620
申请日：2002-04-11
申请人： 주식회사 엘지생명과학
发明人： 박태교 , 박종우 , 방찬식 , 김윤식 , 박희동 , 김태훈 , 이선화 , 김호준 , 김은경 , 오윤경 , 조승주 , 김미선 , 김용주
IPC分类号： C07D403/12
摘要： PURPOSE: Selective thrombin inhibitors having an aminopyridoaryl group are provided, which thrombin inhibitors have improved thrombin inhibiting activity, improves selectivity to thrombin and improved oral absorption rate. CONSTITUTION: Selective thrombin inhibitors represented by the formula 1, and pharmaceutically acceptable salts, prodrugs, hydrides, solvates and isomers thereof are provided, wherein Q is aminopyridoaryl; W is hydrogen, alkyl(C=1-8), diarylmethyl(C=6-10), arylalkyl(C=5-12), heteroaryl(C=4-10), heteroarylalkyl(C=5-11), dicycloalkylmethyl(C=3-6) or cycloalkyl(C=3-8); X and Y are independently selected from the group consisting of hydrogen, alkyl(C=1-8), cycloalkyl(C=3-8), alkoxycarbonylalkyl, cyanoalkyl, carboxyalkyl, hydroxyalkyl, alkyloxyalkyl, dialkylaminocarbonylalkyl, monoalkylaminocarbonylalkyl, aminocarbonylalkyl, methanesulfonyl, and O-alkyloxalyl; and n is 0, 1 or 2.
摘要翻译：目的：提供具有氨基吡啶基芳基的选择性凝血酶抑制剂，其凝血酶抑制剂具有改善的凝血酶抑制活性，提高对凝血酶的选择性和改善的口服吸收率。构成：提供由式1表示的选择性凝血酶抑制剂及其药学上可接受的盐，前药，氢化物，溶剂化物和异构体，其中Q是氨基吡啶并芳基; W是氢，烷基（C = 1-8），二芳基甲基（C = 6-10），芳基烷基（C = 5-12），杂芳基（C = 4-10），杂芳基烷基（C = 5-11），二环烷基甲基（C = 3-6）或环烷基（C = 3-8）; X和Y独立地选自氢，烷基（C = 1-8），环烷基（C = 3-8），烷氧基羰基烷基，氰基烷基，羧基烷基，羟基烷基，烷氧基烷基，二烷基氨基羰基烷基，单烷基氨基羰基烷基，氨基羰基烷基，甲磺酰基和 O型alkyloxalyl; n为0,1或2。

8. 发明授权

KR100392468B1 사이클린 의존 키나아제의 저해제로서 유용한3-히드록시크로멘-4-온 유도체 失效
标题翻译： 사이클린의존키나아제의저해제로서유용한3-히드록시크로멘-4-온유도체
公开(公告)号：KR100392468B1
公开(公告)日：2003-07-22
申请号：KR1020000054577
申请日：2000-09-18
申请人： 주식회사 엘지생명과학
发明人： 홍창용 , 이진호 , 박태식 , 김종현 , 최세현 , 윤숙경 , 정신우 , 김동명 , 김은경
IPC分类号： C07D405/04
摘要： PURPOSE: Provided are 3-Hydroxychromen-4-on derivatives useful as cyclin dependent kinase inhibitors, their pharmaceutically acceptable salts, hydrates, solvates and enantiomers. Also, provided are their manufacturing method, and an anti-cancer composition containing pharmaceutically acceptable carrier and the above compounds as active ingredients and having excellent antiproliferative effects to be effective in inhibiting and treating diseases relating to cell growth, such as cancer, inflammation, angiogenesis or the like. CONSTITUTION: 3-Hydroxychromen-4-on derivatives are represented by the formula(1), (2) and (3), wherein R1 is hydrogen, alkyl, amino alkyl or hydroxy alkyl group; R2 is hydrogen, methyl, trifluoromethyl or halogen; R3 is alkyl, amino alkyl or hydroxyl alkyl group; and X is halogen.
摘要翻译：目的：提供可用作细胞周期蛋白依赖性激酶抑制剂的3-羟基苯并吡喃-4-酮衍生物，它们的药学上可接受的盐，水合物，溶剂合物和对映异构体。此外，还提供了它们的制造方法，以及含有药学上可接受的载体和上述化合物作为活性成分并且具有优异的抗增殖作用以有效抑制和治疗与细胞生长相关的疾病如癌症，炎症，血管生成的抗癌组合物或类似的。构成：3-羟基苯并吡喃-4-酮衍生物由式（1），（2）和（3）表示，其中R 1为氢，烷基，氨基烷基或羟烷基; R2是氢，甲基，三氟甲基或卤素; R3是烷基，氨基烷基或羟基烷基; 和X是卤素。

9. 发明公开

KR1020020074683A 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법 无效
标题翻译：有害的2,4-二吡啶衍生物及其生产
公开(公告)号：KR1020020074683A
公开(公告)日：2002-10-04
申请号：KR1020010014624
申请日：2001-03-21
申请人： 주식회사 엘지생명과학
发明人： 임재홍 , 최종류 , 김정민 , 조동규 , 노기윤 , 황재택 , 이장호 , 장현숙 , 조우영 , 김은경
IPC分类号： C07D239/46
摘要： PURPOSE: A process of preparing new 2,4-pyrimidinedione derivatives having high antiviral activity against Hepatitis B virus and low toxicity is provided. Whereby, the composition can be effectively used in treatment and prevention of Hepatitis B virus. CONSTITUTION: The titled compound of the formula 1 is prepared by alkylation of a compound of formula 2 with a compound of a formula R-X or 3b. In formula, R, R2 and R3 are each independently H or C1-8 alkyl, with the proviso that R1, R2 and R3 are the same at the same time, A represents two hydrogen atoms, CH2, O, S or NH, Ar represents phenyl or naphtyl capable of being substituted by a substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, amino and C1-4 alkylamino, X represents halogen.
摘要翻译：目的：提供一种制备具有抗乙型肝炎病毒抗病毒活性和毒性低的新型2,4-嘧啶二酮衍生物的方法。因此，该组合物可有效地用于治疗和预防乙型肝炎病毒。构成：式1的标题化合物通过用式R-X或3b的化合物烷基化式2的化合物来制备。在式中，R，R 2和R 3各自独立地为H或C 1-8烷基，条件是R 1，R 2和R 3同时相同，A表示两个氢原子，CH 2，O，S或NH，Ar 表示能够被选自C 1-4烷基，C 1-4烷氧基，氨基和C 1-4烷基氨基的取代基取代的苯基或萘基，X表示卤素。

10. 发明公开

KR1020020021851A 사이클린 의존 키나아제의 저해제로서 유용한3-히드록시크로멘-4-온 유도체 失效
标题翻译：作为循环依赖性激酶抑制剂有用的3-羟基吡喃-4-酮衍生物
公开(公告)号：KR1020020021851A
公开(公告)日：2002-03-23
申请号：KR1020000054577
申请日：2000-09-18
申请人： 주식회사 엘지생명과학
发明人： 홍창용 , 이진호 , 박태식 , 김종현 , 최세현 , 윤숙경 , 정신우 , 김동명 , 김은경
IPC分类号： C07D405/04
摘要： PURPOSE: Provided are 3-Hydroxychromen-4-on derivatives useful as cyclin dependent kinase inhibitors, their pharmaceutically acceptable salts, hydrates, solvates and enantiomers. Also, provided are their manufacturing method, and an anti-cancer composition containing pharmaceutically acceptable carrier and the above compounds as active ingredients and having excellent antiproliferative effects to be effective in inhibiting and treating diseases relating to cell growth, such as cancer, inflammation, angiogenesis or the like. CONSTITUTION: 3-Hydroxychromen-4-on derivatives are represented by the formula(1), (2) and (3), wherein R1 is hydrogen, alkyl, amino alkyl or hydroxy alkyl group; R2 is hydrogen, methyl, trifluoromethyl or halogen; R3 is alkyl, amino alkyl or hydroxyl alkyl group; and X is halogen.
摘要翻译：目的：提供可用作细胞周期蛋白依赖性激酶抑制剂，其药学上可接受的盐，水合物，溶剂合物和对映异构体的3-羟基色烯-4-基衍生物。此外，其制造方法以及含有药学上可接受的载体的抗癌组合物和上述化合物作为活性成分，并且具有优异的抗增殖作用，可有效抑制和治疗与细胞生长有关的疾病，例如癌症，炎症，血管生成或类似物。构成：3-羟基苯并噻喃-4-酮衍生物由式（1），（2）和（3）表示，其中R 1是氢，烷基，氨基烷基或羟基烷基; R2是氢，甲基，三氟甲基或卤素; R3是烷基，氨基烷基或羟基烷基; X为卤素。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式